Stay updated on Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.

Latest updates to the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2. This change does not modify the study details or eligibility criteria.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoval of the government funding/status notice; core study information including interventions, eligibility criteria, and outcomes remains unchanged. The administrative notice removed does not affect the study details or enrollment processes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedThe changes are limited to minor formatting and wording updates on the Study Details page and do not affect core content such as eligibility criteria, outcomes, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference3%

- Check78 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0.SummaryDifference0.1%

- Check93 days agoChange DetectedThe page now shows revision v3.0.2 instead of v3.0.1, and the 'Back to Top' link was removed; core content remains the same.SummaryDifference0.2%

Stay in the know with updates to Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.